Posts

Intelligence-led Assessment of Pharmaceuticals in the Environment (iPiE)

Active pharmaceutical ingredients (APIs) of medicines for human use can be released to the environment during the manufacturing process, following use by patients or when unused medicines are disposed of in an incorrect manner. As APIs are biologically active compounds, concerns have been raised about the potential effects of APIs in the environment on human […]

Development of effective measures to reduce the environmental risk of human and veterinary pharmaceuticals

The environmental risks related to human and veterinary pharmaceuticals have to be assessed according to legal requirements within the authorisation procedures for pharmaceuticals. If a risk for the environment is indicated, risk mitigation measures should be proposed by the applicant and implemented within the risk management. The authorisation of a veterinary pharmaceutical can be refused […]

Environmental risk assessment of pharmaceuticals (ERAPharm)

The widespread detection of a large variety of pharmaceuticals in the environment has raised concern about the potential impact of these bioactive substances on the environment. The overall aim of ERAPharm was to advance existing knowledge and methods for the environmental risk assessment of pharmaceuticals. Within the three years of the project, the impact of […]